DSpace About DSpace Software 日本語
 

GINMU >
01 奈良県立医科大学 >
012 大学院 >
0122 学位請求論文 >
01221 博士論文(医学) >
2023年度 >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10564/4358

Title: Regulation of von Willebrand factor by ADAMTS13 ameliorates lipopolysaccharide-induced lung injury in mice
Other Titles: ADAMTS13によるvon Willebrand因子の制御はマウスにおけるLPS誘発肺炎病態を改善する
Authors: Onodera, Yu
Mitani, Seiji
Hosoda, Chihiro
Takabayashi, Yoko
Sakata, Asuka
Kawasaki, Ryohei
Mori, Ryota
Ohshima, Chiaki
Nishio, Kenji
Sugimoto, Mitsuhiko
Soejima, Kenji
Mackman, Nigel
Shima, Midori
Tatsumi, Kohei
Keywords: ADAMTS13
Inflammation
Lipopolysaccharides
Lung
Von Willebrand factor
Issue Date: Dec-2023
Publisher: Springer
Citation: International Journal of Hematology. 2023 Dec, vol.118, no.6, p.699-710
Abstract: The relationship between von Willebrand factor (VWF) and inflammation has attracted considerable attention in recent years. VWF, which is stored in the Weibel-Palade bodies (WPBs) of endothelial cells (ECs), is released from WPBs in response to inflammatory stimuli and is thought to contribute to inflammation by promoting leukocyte extravasation. In this study, lung injury model mice were produced by intratracheal injection with lipopolysaccharides. The severity of lung inflammation was evaluated in mice with different genotypes (wild-type, Vwf-/-, Adamts13-/-) and mice treated with drugs that inhibit VWF function. Lung inflammation was significantly ameliorated in Vwf-/- mice compared with wild-type mice. Furthermore, inflammation was significantly suppressed in wild-type mice treated with anti-VWF A1 antibody or recombinant human ADAMTS13 compared with the untreated control group. The underlying mechanism appears to be an increased VWF/ADAMTS13 ratio at the site of inflammation and the interaction between blood cell components, such as leukocytes and platelets, and the VWF A1 domain, which promotes leukocyte infiltration into the lung. This study suggested that ADAMTS13 protein and other VWF-targeting agents may be a novel therapeutic option for treatment of pulmonary inflammatory diseases.
Description: 本文は発行元が定める公開猶予期間終了後に公開
URI: http://hdl.handle.net/10564/4358
ISSN: 0925-5710
DOI: https://doi.org/10.1007/s12185-023-03668-x
Academic Degrees and number: 24601甲第907号
Degree-granting date: 2024-03-14
Degree name: 博士(医学)
Degree-granting institutions: 奈良県立医科大学
Appears in Collections:2023年度

Files in This Item:

File Description SizeFormat
1甲907本文の要旨.pdf甲907本文の要旨110.78 kBAdobe PDFView/Open
2甲907審査要旨.pdf甲907審査要旨212.71 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback